The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs
Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms invol...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/3/1702 |
| _version_ | 1797318647227613184 |
|---|---|
| author | Erminia Ridolo Alessandro Barone Martina Ottoni Silvia Peveri Marcello Montagni Francesca Nicoletta |
| author_facet | Erminia Ridolo Alessandro Barone Martina Ottoni Silvia Peveri Marcello Montagni Francesca Nicoletta |
| author_sort | Erminia Ridolo |
| collection | DOAJ |
| description | Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms involved in the pathogenesis of EoE and biologics, in particular monoclonal antibodies (mAbs), targeting these pathways are needed. Currently, the most relevant is dupilumab, which interferes with both interleukin (IL)-4 and IL-13 pathways by binding IL-4 receptor α, and is the only mAb approved by the European Medicine Agency and US Food and Drug Administration for the treatment of EoE. Other mAbs investigated include mepolizumab, reslizumab, and benralizumab (interfering with IL-5 axis), cendakimab and dectrekumab (anti-IL-13s), tezepelumab (anti-TSLP), lirentelimab (anti-SIGLEG-8), and many others. Despite the undeniable economic impact of biologic therapies, in the near future, there will be room for further reflection about the opportunity to prescribe biologic agents, not only as a last-line therapy in selected cases such as patients with comorbidities involving common pathways. Although recent findings are very encouraging, the road to permanent success in the treatment of EoE is still long, and further studies are needed to determine the long-term effects of mAbs and to discover new potential targets. |
| first_indexed | 2024-03-08T03:55:23Z |
| format | Article |
| id | doaj.art-2a4ea6bb9ed54470b0df5678d049a47c |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T03:55:23Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-2a4ea6bb9ed54470b0df5678d049a47c2024-02-09T15:14:16ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-01-01253170210.3390/ijms25031702The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological DrugsErminia Ridolo0Alessandro Barone1Martina Ottoni2Silvia Peveri3Marcello Montagni4Francesca Nicoletta5Department of Medicine and Surgery, University of Parma, 43121 Parma, ItalyDepartment of Medicine and Surgery, University of Parma, 43121 Parma, ItalyDepartment of Medicine and Surgery, University of Parma, 43121 Parma, ItalyDepartmental Unit of Allergology, Guglielmo da Saliceto Hospital, 29121 Piacenza, ItalyDepartmental Unit of Allergology, Guglielmo da Saliceto Hospital, 29121 Piacenza, ItalyDepartment of Medicine and Surgery, University of Parma, 43121 Parma, ItalyEosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms involved in the pathogenesis of EoE and biologics, in particular monoclonal antibodies (mAbs), targeting these pathways are needed. Currently, the most relevant is dupilumab, which interferes with both interleukin (IL)-4 and IL-13 pathways by binding IL-4 receptor α, and is the only mAb approved by the European Medicine Agency and US Food and Drug Administration for the treatment of EoE. Other mAbs investigated include mepolizumab, reslizumab, and benralizumab (interfering with IL-5 axis), cendakimab and dectrekumab (anti-IL-13s), tezepelumab (anti-TSLP), lirentelimab (anti-SIGLEG-8), and many others. Despite the undeniable economic impact of biologic therapies, in the near future, there will be room for further reflection about the opportunity to prescribe biologic agents, not only as a last-line therapy in selected cases such as patients with comorbidities involving common pathways. Although recent findings are very encouraging, the road to permanent success in the treatment of EoE is still long, and further studies are needed to determine the long-term effects of mAbs and to discover new potential targets.https://www.mdpi.com/1422-0067/25/3/1702biological drugsbenralizumabcendakimabdupilumabeosinophilic esophagitislirentelimab mepolizumab |
| spellingShingle | Erminia Ridolo Alessandro Barone Martina Ottoni Silvia Peveri Marcello Montagni Francesca Nicoletta The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs International Journal of Molecular Sciences biological drugs benralizumab cendakimab dupilumab eosinophilic esophagitis lirentelimab mepolizumab |
| title | The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs |
| title_full | The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs |
| title_fullStr | The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs |
| title_full_unstemmed | The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs |
| title_short | The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs |
| title_sort | new therapeutic frontiers in the treatment of eosinophilic esophagitis biological drugs |
| topic | biological drugs benralizumab cendakimab dupilumab eosinophilic esophagitis lirentelimab mepolizumab |
| url | https://www.mdpi.com/1422-0067/25/3/1702 |
| work_keys_str_mv | AT erminiaridolo thenewtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT alessandrobarone thenewtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT martinaottoni thenewtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT silviapeveri thenewtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT marcellomontagni thenewtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT francescanicoletta thenewtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT erminiaridolo newtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT alessandrobarone newtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT martinaottoni newtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT silviapeveri newtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT marcellomontagni newtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs AT francescanicoletta newtherapeuticfrontiersinthetreatmentofeosinophilicesophagitisbiologicaldrugs |